Prescription-Event Monitoring in New Zealand

Mann's Pharmacovigilance: Third Edition

Volumn , Issue , 2014, Pages 385-402

  Harrison Woolrych, Mira ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

Cohort event monitoring studies; Dispensing data; Electronic data capture; Intensive medicines monitoring programme (IMMP) methods; New Zealand; Prescription event monitoring (PEM)

Indexed keywords

EID: 84926432318     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781118820186.ch23     Document Type: Chapter

References (59)

1. Beggs, P.W., Clarke, D.W.J, Williams, S.M., & Coulter, D.M. (1999) A comparison of the use, effectiveness and safety of bezafibrate, gemfibrozil and simvastatin in normal clinical practice using the New Zealand Intensive Medicines Monitoring Programme (IMMP). Br J Clin Pharmacol, 47, 99-104.
2. Clark, D.W.J. & Coulter, D.M. (2003) Psoriasis associated with rofecoxib use. Arch Dermatol, 139, 1223.
3. Clark, D.W. & Harrison-Woolrych, M.L. (2004) Sibutramine may be associated with memory impairment. BMJ, 329, 1316.
4. Clark, D.W.J. & Harrison-Woolrych, M.L. (2006) The role of the New Zealand Intensive Medicines Monitoring Programme in identification of previously unrecognised signals of adverse drug reactions. Curr Drug Saf, 1 (2), 169-178.
5. Clark, D.W.J., Donnelly, E., Coulter, D.M. et al. (2004) Linking pharmacovigilance with pharmacogenetics. Drug Saf, 7 (15), 1171-1184.
6. Coulter, D.M. (1979) A comparison of scalp tingling, thirst and polyuria in patients on labetalol and metoprolol. N Z Med J, 90, 397.
7. Coulter, D.M. (1981) Study of reasons for cessation of therapy with perhexiline maleate, sodium valproate and labetalol in the intensified adverse drug reaction reporting scheme. N Z Med J, 93, 81-84.
8. Coulter, D.M. (1986) Pilot trial in the use of duplicate prescription pads for the Intensified Adverse Drug Reaction Reporting Scheme. In: Research Review, pp. 180-181. The Medical Research Council of New Zealand, Auckland
9. Coulter, D.M. (1988) Eye pain with nifedipine and disturbance of taste with captopril: a mutually controlled study showing a method of postmarketing surveillance. Br Med J, 296, 1086-1088.
10. Coulter, D.M. (1998) The New Zealand Intensive Medicines Monitoring Programme. Pharmacoepidemiol Drug Saf, 7, 79-90.
11. Coulter, D.M. (2000) The New Zealand Intensive Medicines Monitoring Programme in pro-active safety surveillance. Pharmacoepidemiol Drug Saf, 9, 273-280.
12. Coulter, D.M. (2001) Privacy issues and the monitoring of sumatriptan in the New Zealand Intensive Medicines Monitoring Programme. Pharmacoepidemiol Drug Saf, 10, 663-667.
13. Coulter, D.M. (2002) Acute psychiatric reactions with COX-2 inhibitors. Prescriber Update, 23 (2), 21.
14. Coulter, D.M. & Edwards, I.R. (1987) Cough associated with captopril and enalapril. Br Med J, 294, 1521-1523.
15. Coulter, D.M. & Edwards, I.R. (1990) Mianserin and agranulocytosis in New Zealand. Lancet, 336, 785-787.
16. Coulter, D.M. & McQueen, E.G. (1982) Post marketing surveillance: achievements and problems in the Intensified Adverse Drug Reaction Reporting Scheme. N Z Fam Physician, 1, 13-17.
17. Coulter, D.M. & Pillans, P. (1993) Angiotensin-converting enzyme inhibitors and psoriasis. N Z Med J, 106, 392-393.
18. Coulter, D.M. & Pillans, P. (1995a) Fluoxetine and extrapyramidal side effects. Am J Psychiatry, 152, 122-125.
19. Coulter, D.M. & Pillans, P.I. (1995b) Hypertension with moclobemide. Lancet, 346, 1032.
20. Coulter, D.M., Clark, D.W.J., & Savage, L.R. (2003a) Celecoxib, rofecoxib and acute temporary visual impairment. BMJ, 327, 1214-1215.
21. Coulter, D.M., Passier, A., Clark, D.W.J., & Van Puijenbroek, E. (2003b) Activation of pain by sumatriptan. Headache, 43, 999-1003.
22. Department of Health (1979) Perhexiline maleate (Pexid). Clinical Services Letter, No. 190, 12 November, p. 3.
23. Department of Health (1980) Perhexiline maleate (Pexid). Clinical Services Letter, No. 192, 11 March, p. 2.
24. Edwards, I.R. & Coulter, D.M. (1989) ACE inhibitors and anaemia. N Z Med J, 102, 325.
25. Edwards, I.R., Coulter, D.M., & Macintosh, D. (1992) Intestinal effects of captopril. BMJ, 304, 359-360.
26. Harrison-Woolrych, M.L. (2003) IMMP studies of the Multiload intrauterine device. Prescriber Update, 24 (2), 31-32.
27. Harrison-Woolrych, M.L. (2010) Varenicline and suicide: safety data from New Zealand. BMJ, 339, b5654.
28. Harrison-Woolrych, M. (2011) Patient reporting encouraged during monitoring of dapoxetine in New Zealand. Drug Saf, 34 (11), 1115-1116.
29. Harrison-Woolrych, M. & Ashton, J. (2010) Utilization of the smoking cessation medicine varenicline: an intensive post-marketing study in New Zealand. Pharmacoepidemiol Drug Saf, 19, 1-5.
30. Harrison-Woolrych, M. & Ashton, J. (2011) Psychiatric adverse events associated with varenicline: an intensive post marketing prospective cohort study in New Zealand. Drug Saf, 34 (9), 1-10.
31. Harrison-Woolrych, M.L. & Clark, D.W. (2004) Epistaxis associated with risperidone. BMJ, 328, 1416.
32. Harrison-Woolrych, M.L., Ashton, J., & Coulter, D.M. (2002) Insertion of the Multiload Cu375 intrauterine device; experience in over 16,000 New Zealand women. Contraception, 66, 387-391.
33. Harrison-Woolrych, M.L., Ashton, J., & Coulter, D.M. (2003a) Uterine perforation on intrauterine device insertion: is the incidence higher than previously reported? Contraception, 67, 53-56.
34. Harrison-Woolrych, M.L., Ashton, J., & Coulter, D.M. (2003b) Insertion of intrauterine devices: a comparison of experience with Mirena and Multiload Cu375 during post-marketing monitoring in New Zealand. N Z Med J, 116, 1179.
35. Harrison-Woolrych, M.L., Herbison, P., McLean, R. et al. (2005) Incidence of thrombotic cardiovascular events in patients taking celecoxib compared with those taking rofecoxib: interim results from the New Zealand Intensive Medicines Monitoring Programme. Drug Saf, 28 (5), 435-442.
36. Harrison-Woolrych, M.L., Clark, D.W.J., Hill, G.R. et al. (2006a) QT interval prolongation associated with sibutramine. Br J Clin Pharmacol, 61 (4), 464-469.
37. Harrison-Woolrych, M.L., Hill, G.R., & Clark, D.W. (2006b) Bruising associated with sibutramine: results from post-marketing surveillance in New Zealand. Int J Obes, 30, 1315-1317
38. Harrison-Woolrych, M.L., Garcia-Quiroga, J., Ashton, J., & Herbison, P. (2007) Safety and usage of atypical antipsychotic medicines in children: a nationwide prospective cohort study. Drug Saf, 30 (7), 569-579.
39. Harrison-Woolrych, M., Jamieson, S., Malik, M. et al. (2011a) Electronic data capture of dispensing data by the New Zealand Intensive Medicines Monitoring Programme: a consultation study of community and hospital pharmacists. Int J Pharm Pract, 19 (2), 136-139.
40. Harrison-Woolrych, M.L., Skegg, K., Ashton, J. et al. (2011b) Nocturnal enuresis in adults taking clozapine, risperidone, olanzapine and quetiapine: a comparative cohort study. Br J Psychiatry, 199, 140-144.
41. Harrison-Woolrych, M., Harmark, L., Tan, M., Maggo, S. and van Grootheest, K. (2012) Epistaxis and other haemorrhagic events associated with the smoking cessation medicine varenicline: a case series from two national pharmacovigilance centres. Eur J Clin Pharmacol, 68(7), 1065-1072.
42. Harrison-Woolrych, M., Paterson, H., & Tan, M. (2013) Exposure to the smoking cessation medicine varenicline during pregnancy: a prospective nationwide cohort study. Pharmacoepidemiol Drug Saf, 22 (10), 1086-1092.
43. Hill, G.R. & Harrison-Woolrych, M.L. (2008) Clozapine and myocarditis: a case series from the New Zealand Intensive Medicines Monitoring Programme. N Z Med J, 121 (1281), 68-74.
44. Hill, G., Harrison-Woolrych, M.L., & Ashton, J. (2007) Sibutramine utilisation in New Zealand: an analysis of prescription data by the Intensive Medicines Monitoring Programme. Pharmacoepidemiol Drug Saf, 16, 1217-1226.
45. Inman, W.H. (1981a) Postmarketing surveillance of adverse drug reactions in general practice I. Search for new methods. Br Med J, 282, 1131-1132.
46. Inman, W.H. (1981b) Postmarketing surveillance of adverse drug reactions in general practice II. Prescription-event monitoring at the University of Southampton. Br Med J, 282, 1216-1217.
47. Kunac, D.L., Harrison-Woolrych, M.L., & Tatley, M.V. (2008) Pharmacovigilance in New Zealand: the role of the New Zealand Pharmacovigilance Centre in facilitating safer medicines use. N Z Med J, 121 (1281), 76-89.
48. McLean, R. & Harrison-Woolrych, M.L. (2007) Alopecia associated with quetiapine. Int Clin Psychopharmacol, 22 (2), 117-119.
49. McQueen, E.G. (1977) Intensified adverse drug reaction reporting scheme. N Z Med J, 85, 296-297.
50. McQueen, E.G. (1982) Drug safety monitoring using recorded release and results with sodium valproate. Adv Pharmacol Ther II, 6, 79-89.
51. Olsson, S. (ed.) (1999) National Pharmacovigilance Systems. Uppsala Monitoring Centre, Uppsala.
52. Palmer, S.E., McLean, R.M., Ellis, P.M., & Harrison-Woolrych, M.L. (2008) Life-threatening clozapine-induced gastro-intestinal hypomotility: an analysis of 102 cases. J Clin Psychiatry, 69 (5), 759-768.
53. Paterson, H., Clifton, J., Miller, D. et al. (2007) Hair loss with use of the levonorgestrel intrauterine device. Contraception, 76 (4), 306-309.
54. Pillans, P.I. & Coulter, D.M. (1994) Fluoxetine and hyponatraemia - a potential hazard in the elderly. N Z Med J, 107, 85-86.
55. Savage, R.L., Coulter, D.M., & Harrison-Woolrych, M.L. (2005) COX-2 inhibitors may cause dysrhythmias. A signal from the Intensive Medicines Monitoring Programme. Drug Saf, 28 (10), 963.
56. Skegg, D.C.G. & Doll, R. (1977) Frequency of eye complaints and rashes among patients receiving practolol and propranolol. Lancet, 310 (8036), 475-478.
57. Tan, M. & Harrison-Woolrych, M. (2013) Memory impairment associated with varenicline: a case series from the New Zealand Intensive Medicines Monitoring Programme. Eur J Clin Pharmacol, 69 (5), 1195-1196.
58. Van Grootheest, A.C., Sachs, B., Harrison-Woolrych, M. et al. (2011) Uterine perforation with the levonorgestrel releasing intrauterine device: analysis of reports from four national pharmacovigilance centres. Drug Saf, 34 (1), 83-88
59. Zhou, L, Harrison-Woolrych, M.L., & Coulter, D.M. (2003) Use of the New Zealand Intensive Medicines Monitoring Programme to study the levonorgestrel-releasing intrauterine device (Mirena). Pharmacoepidemiol Drug Saf, 12, 371-377.